Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05738772 | Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer(ICONIC) | unknown | Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 21, 2023 |
| clinicaltrials |
| NCT04997798 | Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05736991 | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | unknown | — | 600 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04992143 | TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | unknown | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05729867 | Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC | unknown | N/A | 50 | Seoul National University HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT03766555 | Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function | unknown | N/A | 76 | Chinese University of Hong KongOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05543304 | Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | unknown | — | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05724758 | Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery | unknown | — | 100 | Brust-Zentrum AGOTHER | 0 | Feb 13, 2023 | clinicaltrials |
| NCT05721300 | Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer | unknown | N/A | 2,215 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT04417764 | TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | unknown | Phase 1 | 10 | Central South UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05720026 | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | unknown | Phase 3 | 560 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05029973 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05225116 | Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05716620 | Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 380 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05717634 | Endometrial Changes in Breast Cancer Women. | unknown | — | 829 | Regina Elena Cancer InstituteOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | unknown | Early Phase 1 | 30 | Ashwin SomasundaramOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04911959 | Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | unknown | Phase 1 / Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05466357 | Application Research on Endoscopic Pseudocapsule-Based Resection for Pituitary Adenomas | unknown | N/A | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05185557 | BRIANSTORM - Early Identification of Patients With Brain Metastases | unknown | — | 50 | Aarhus University HospitalOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT04605237 | Pancreatic Cancer Recurrence in the Netherlands | unknown | — | 1,750 | UMC UtrechtOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT04612504 | SynOV1.1 Intratumoral Injection Study | unknown | Phase 1 | 15 | Beijing Syngentech Co., Ltd.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05339607 | Endoscopic Resection of Papillary Adenomas; a Novel Treatment Algorithm to Prevent Recurrence - a Pilot-study (ERASE-pilot)(ERASE-pilot) | unknown | N/A | 20 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05701553 | Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma | unknown | — | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05609695 | Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma | unknown | — | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05705583 | A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma | unknown | — | 100 | Zhejiang Cancer HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05705635 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | unknown | Phase 2 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05707338 | Short-term Outcomes of Laparoscopic Versus Open Gastrectomy With Lymph Node Dissection for Early Gastric Cancer :a Randomized Controlled Study | unknown | N/A | 40 | Sohag UniversityOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05131698 | Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | unknown | Early Phase 1 | 31 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05312216 | Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05690412 | Efficacy and Safety of Endoscopic Papillectomy in the Treatment of Ampullary Neoplasms.(PaNETh) | unknown | — | 400 | Azienda Unità Sanitaria Locale della RomagnaOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05692661 | A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer | unknown | Phase 1 | 24 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04248998 | Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer(BREAKFAST) | unknown | Phase 2 | 30 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04582968 | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases | unknown | Phase 1 / Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04213118 | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence(ALTER-H-004) | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05686720 | Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer | unknown | Early Phase 1 | 12 | First Affiliated Hospital of Shantou University Medical CollegeOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05043532 | Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer | unknown | N/A | 33 | Orlando Health, Inc.OTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05680662 | The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism | unknown | Early Phase 1 | 200 | Ministry of Health, Saudi ArabiaOTHER_GOV | 0 | Jan 11, 2023 | clinicaltrials |
| NCT05677724 | Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment | unknown | — | 20 | Fubing WangOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT05668793 | GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method) | unknown | — | 1,000 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05557656 | A Real World Study of Regogfinib in HCC | unknown | — | 800 | Zhongda HospitalOTHER | 0 | Dec 29, 2022 | clinicaltrials |
| NCT05631613 | Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma | unknown | — | 40 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 22, 2023source: clinicaltrials